BACKGROUND: Because fewer than 1000 cases of primary adenocarcinoma of the duodenum have been reported, earlier series are limited by local referral patterns and the long periods of time needed for retrospective reviews. METHODS: This study reports the outcomes of preiampullary duodenal adenocarcinoma treatments in all hospitals of the Department of Veterans Affairs from 1987 through 1991, using computer and tumor registry records. Patients were grouped by their most aggressive treatment (resection > operative bypass > percutaneous biliary intubation) and survival calculated from the date of this procedure. RESULTS: Of 2185 patients with periampullary cancers (1753 pancreatic, 432 other periampullary), 85 were duodenal and thus comprised only 4% of periampullary tumors. Thirty-four duodenal cancers were resected, 44 bypassed, and 7 had biliary intubation, with 30-day mortality rates of 6%, 18%, and 0%, respectively. Mean survival exceeded 1 year in all groups, and resection resulted in a significant increase in mean survival (784 vs. 438 days for nonresection, P = 0.01). The projected 5-year survival rate after resection was 23%. Mean survival after resection of 9 Stage I-II cancers was 668 days, but was similar after 5 resections with nodal or other metastases. Similarly, survival did not correlate with cancer stage in 13 palliated patients. CONCLUSIONS: This large study of patients with duodenal cancer provides a unique perspective of disease prevalence and response to surgical treatment. Prolonged survival is common with any treatment, but the longest survivals were after resection.
BACKGROUND: Because fewer than 1000 cases of primary adenocarcinoma of the duodenum have been reported, earlier series are limited by local referral patterns and the long periods of time needed for retrospective reviews. METHODS: This study reports the outcomes of preiampullary duodenal adenocarcinoma treatments in all hospitals of the Department of Veterans Affairs from 1987 through 1991, using computer and tumor registry records. Patients were grouped by their most aggressive treatment (resection > operative bypass > percutaneous biliary intubation) and survival calculated from the date of this procedure. RESULTS: Of 2185 patients with periampullary cancers (1753 pancreatic, 432 other periampullary), 85 were duodenal and thus comprised only 4% of periampullary tumors. Thirty-four duodenal cancers were resected, 44 bypassed, and 7 had biliary intubation, with 30-day mortality rates of 6%, 18%, and 0%, respectively. Mean survival exceeded 1 year in all groups, and resection resulted in a significant increase in mean survival (784 vs. 438 days for nonresection, P = 0.01). The projected 5-year survival rate after resection was 23%. Mean survival after resection of 9 Stage I-II cancers was 668 days, but was similar after 5 resections with nodal or other metastases. Similarly, survival did not correlate with cancer stage in 13 palliated patients. CONCLUSIONS: This large study of patients with duodenal cancer provides a unique perspective of disease prevalence and response to surgical treatment. Prolonged survival is common with any treatment, but the longest survivals were after resection.
Authors: George A Poultsides; Lyen C Huang; John L Cameron; Richard Tuli; Leslie Lan; Ralph H Hruban; Timothy M Pawlik; Joseph M Herman; Barish H Edil; Nita Ahuja; Michael A Choti; Christopher L Wolfgang; Richard D Schulick Journal: Ann Surg Oncol Date: 2011-12-14 Impact factor: 5.344
Authors: So Youn Park; Ji Kon Ryu; Ju Hee Park; Hyuk Yoon; Ji Yeon Kim; Yong Bum Yoon; Jae-Gahb Park; Sang Hyub Lee; Sung-Bum Kang; Ji Won Park; Jae Hwan Oh Journal: Gut Liver Date: 2011-03-16 Impact factor: 4.519
Authors: Edwin O Onkendi; Sarah Y Boostrom; Michael G Sarr; Michael B Farnell; David M Nagorney; John H Donohue; Michael L Kendrick; Kaye M Reid-Lombardo; William S Harmsen; Florencia G Que Journal: J Gastrointest Surg Date: 2012-02-17 Impact factor: 3.452
Authors: Fábio Guilherme Campos; Carlos Augusto Real Martinez; Leonardo Alfonso Bustamante Lopez; Danilo Toshio Kanno; Sérgio Carlos Nahas; Ivan Cecconello Journal: J Gastrointest Oncol Date: 2017-10
Authors: Woo Chul Chung; Chang Nyol Paik; Sung Hoon Jung; Kang-Moon Lee; Sang Woo Kim; U-Im Chang; Jin Mo Yang Journal: Korean J Intern Med Date: 2011-03-02 Impact factor: 2.884
Authors: T A Sohn; K D Lillemoe; J L Cameron; H A Pitt; H S Kaufman; R H Hruban; C J Yeo Journal: J Gastrointest Surg Date: 1998 Jan-Feb Impact factor: 3.267